Will it matter?

Will it matter?

Yesterday Lilly (NYSE: LLY) released their Integrated Summary Report which contained a section on how the company prices their medications. According to the report the company acknowledged what everyone already that they have been raising the list price for drugs. They also acknowledged another obvious fact their net effective selling price, what the company actually receives after rebates and discounts barley moved at all. This is particularly true in the highly competitive insulin market . . .

This content is restricted to subscribers. Please subscribe.

Already have an account? Please login.